Oncology Institute of Southern Switzerland (IOSI) at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Oncology Institute of Southern Switzerland (IOSI) takes part in 7 sessions at ESMO 2026 in Madrid. Its program centres on metastatic castration-resistant prostate cancer, from combination strategies to care after progression, and on long-term survival in mismatch repair-deficient endometrial cancer. Other sessions cover recurrent BRCA-mutated ovarian cancer during PARP inhibitor treatment and learning from setbacks in oncology.
| Organization | ESMO 2026 Attendance |
|---|---|
Oncology Institute of Southern Switzerland (IOSI) Bellinzona, Switzerland | |
Cancer institute of the Ticino public cantonal hospital network, based in Bellinzona, Switzerland. | Talk Fri Oct 23 16:15–17:15 Satellite Fri Oct 23 18:50–19:15 Navigating long-term survival in dMMR/MSI-H EC: The clinicians’ experience Gynaecological cancers Satellite Fri Oct 23 19:15–19:40 Mapping change: Evolving clinical practice and conversations Gynaecological cancers Chair Sat Oct 24 10:15–11:45 Proffered paper: Genitourinary tumours, prostate, penile and testils Genitourinary cancers Abstract Sat Oct 24 10:35–10:47 Invited Discussant 2215O and 2216O Genitourinary cancers Talk Sat Oct 24 11:51–11:58 Abstract Sat Oct 24 17:54–18:06 Invited Discussant LBA4 Lung & thoracic cancersMelanoma & skin cancersGenitourinary cancers Satellite Sun Oct 25 18:55–19:10 Satellite Sun Oct 25 19:10–19:30 Satellite Sun Oct 25 19:30–19:45 Satellite Sun Oct 25 19:45–19:55 Questions and Answers Session: Expert Insights for Your Compelling Questions Genitourinary cancers Talk Mon Oct 26 10:15–10:20 Presentation of case/condition Gynaecological cancers Talk Mon Oct 26 11:00–11:20 Systemic therapy for recurrent BRCAmut HGSOC during PARPi Gynaecological cancers |
Instantly find 20 buyers from Oncology Institute of Southern Switzerland (IOSI)
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction